Dilawari A, Cangiarella J, Smith J, Huang A, Downey A, Muggia F
Department of Medical Oncology, NYU Langone School of Medicine, New York, NY 10016, USA.
Ecancermedicalscience. 2008;2:109. doi: 10.3332/ecancer.2008.109. Epub 2008 Nov 25.
The co-existence of breast and ovarian cancers in the same individual should raise suspicion of a hereditary process. Patients with either BRCA1 or BRCA2 germ-line mutations have an average risk of 39% and 11% respectively of developing ovarian cancer by the age of 70; they have a risk of 35-85% of developing breast cancer in their lifetime. We report here unusual pathologic features in a BRCA2 germ-line mutation carrier recently diagnosed with synchronous breast and ovarian cancers, and summarize the findings in six other women who were diagnosed with ovarian cancer either simultaneously with the diagnosis of breast cancer or at varying times after the diagnosis. While in most instances this may be a coincidental occurrence in highly susceptible individuals, the patient we highlight raises the provocative hypothesis that at times breast cancer metastasizes to the ovaries of mutation carriers and stimulates the development of an ovarian cancer as well as other cancers. In addition, these ovarian cancers may have different mechanisms of metastases predisposing them to travel to unusual sites.
同一个体同时患有乳腺癌和卵巢癌应引起对遗传过程的怀疑。携带BRCA1或BRCA2种系突变的患者到70岁时患卵巢癌的平均风险分别为39%和11%;她们一生中患乳腺癌的风险为35%至85%。我们在此报告一名最近被诊断为同步性乳腺癌和卵巢癌的BRCA2种系突变携带者的不寻常病理特征,并总结另外六名在诊断乳腺癌时或之后不同时间被诊断为卵巢癌的女性的研究结果。虽然在大多数情况下,这可能是高度易感个体中的偶然事件,但我们所强调的患者提出了一个具有启发性的假设,即有时乳腺癌会转移到突变携带者的卵巢,并刺激卵巢癌以及其他癌症的发生。此外,这些卵巢癌可能有不同的转移机制,使它们易于转移到不寻常的部位。